Bortezomib, soluble in DMSO and insoluble in ethanol and water, interferes with the proteasome’s ability to degrade proteins, thereby disrupting cellular processes in cancer cells, particularly multiple myeloma. It targets 20S proteasome.
Bortezomib is a proteasome inhibitor used to investigate protein degradation pathways and their therapeutic potential in cancer treatment, especially multiple myeloma.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.